Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
Condition: Acute Chest Syndrome; Sickle Cell Disease
MeSH terms: Acute Chest Syndrome; Anemia, Sickle Cell; Syndrome
Intervention: Unfractionated heparin
Intervention MeSH terms: Heparin; Calcium heparin
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 7.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Sickle cell disease; Acute chest syndrome; Hemoglobinopathy; Hemolytic anemia; Heparin; Anticoagulant

Summary:

      The purpose of this study is to determine the feasibility of performing a larger multicenter
      phase III trial to assess the effects of unfractionated heparin (UFH) in acute chest syndrome
      (ACS). Prespecified feasibility criteria consists of the ability to enroll potential study
      participants, which includes the timely notification of hospitalized patients with ACS, the
      capacity to consent eligible individuals, and the ability to appropriately randomize eligible
      patients within 24 hours of diagnosis. Additional feasibility objectives involve ensuring
      appropriate eligibility criteria, proper administration of the study drug, and the ability to
      completely and accurately collect clinical data of interest. The final aim of our pilot study
      is to provide preliminary data, with respect to treatment effect and variance, to allow
      sample size calculation in a larger trial given the lack of data available to help guide this
      process. The investigators hypothesize that the use of UFH in ACS will result in a decrease
      in the duration of hospitalization and improve other clinical outcomes, such as the duration
      of hypoxemia and duration of moderate to severe pain.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of ACS defined as a new pulmonary infiltrate involving at least one segment
             of the lung on a chest x-ray or chest CT scan with 2 or more of the following: chest
             pain, tachypnea, dyspnea, cough, hypoxemia, or body temperature greater than or equal
             to 38.0 degrees Celsius

          -  Hemoglobin electrophoresis confirming HbSS, SC, or B0 (historical records sufficient)

          -  Age greater than or equal to 18

        Exclusion Criteria:

          -  Any absolute contraindication to heparin

          -  Platelet count less than 50 per microliter (current admission)

          -  Historical diagnosis of moyamoya disease as documented in medical records

          -  Historical diagnosis of proliferative retinopathy as documented in medical records

          -  Current participation in a chronic exchange transfusion program

          -  Underlying hypercoagulable disorder other than sickle cell disease

          -  Currently receiving therappeutic anticoagulation

          -  Currently receiving antiplatelet agents

          -  Currently receiving estrogen containing oral contraceptives

          -  Chest CT scan documented PE performed as standard of care prior to study enrollment
             (current admission)